In the pathophysiology of non-genetic forms of kidney disease, such as diabetic nephropathy, focal segmental glomerulosclerosis, renal fibrosis and immune-mediated kidney diseases, TRPC6 has been involved, and thus, it is considered as a significant marker for the advance of therapeutic mediators to treat various kidney pathologies [13,66]. This evidence concerns the gene TRPC6 and diabetic kidney disease.